Late Stage

Products in Late Stage Development

Spectrum has two late-stage drug candidates including ROLONTIS® (eflapegrastim), a novel, long-acting granulocyte colony-stimulating factor (G-CSF) that is being investigated for the treatment of chemotherapy-induced neutropenia in patients with breast cancer, and Apaziquone for Intravesical Instillation, a synthetic bio-reductive agent being investigated in the treatment of non-muscle invasive bladder cancer.

ROLONTIS® (eflapegrastim) Apaziquone